Isabella Ciccone, Assistant Editor, NeurologyLive®, has been with the team since September 2022. Follow her on Twitter @iciccone7 or email her at email@example.com
Need for Improving Measurements to Track Fatigue in MS
Federica Picariello, PhD, postdoctoral researcher, psychologist, King's College, London, spoke about fatigue mechanisms in patients with MS based on presentations from the 2022 ECTRIMS Congress.
Racial Disparities Reported in the Initial Presentation of ALS
A retrospective study presented at the 2022 Annual NEALS Meeting reported health disparities in the initial presentation of Black patients with ALS in comparison with White patients.
The ALS MOTOR as a Beneficial and Accessible Tool for Virtually Tracking ALS Progression
Christina Fournier, MD, MSc, associate professor of neurology, Emory University, discussed her presentation at the 2022 NEALS Consortium using a telemedicine exam to track ALS progression.
Insomnia-Related Symptoms Possibly Linked to Frequency of Alcohol and Cannabis Use in Late Adolescence
A longitudinal study showed that there were higher levels of alcohol and cannabis use in late adolescent stages who had poor sleep health.
Antibody Levels in Evobrutinib-Treated Relapsing Multiple Sclerosis Increased Following COVID-19 Vaccination
Findings from a randomized phase 2 trial resulted in patients with relapsing multiple sclerosis treated with evobrutinib displaying an increase in S1/S2 IgG antibody levels.
Top News for World Stroke Day
In honor of World Stroke Day, held September 29, 2022, get caught up on some of the latest news in stroke as the NeurologyLive® team shares some of our data updates and expert insights.
Autologous Hematopoietic Stem Cell Transplantation Fails to Show Superiority to Natalizumab as a Treatment for Progressive MS
Presented as an oral late breaker by Tomas Kalincik, MD, PhD, autologous hematopoietic stem cell transplantation was not superior to natalizumab in the reduction of disability progression in patients with progressive MS.
Specific Risk Factors Related to Permanent Disability in NMOSD Identified
Permanent disability, found in 51% of patients with NMOSD at follow-up, was attributed mainly to age of disease onset, delay in diagnosis, and initial EDSS score.
Inadequate Sleep Related to Neurocognitive Difficulties for Children with Insomnia
Fan Nils Yang, PhD, postdoctoral researcher, University of Maryland, provides greater detail on the observational cohort study he did with colleagues, where they identified a link between neurocognitive function in children and insomnia.
Melatonin Treatment Approved by MHRA for Children With ADHD and Sleep Onset Insomnia
Based on a trial that showed melatonin improved total sleep time in children with ADHD and sleep onset insomnia, Colonis’ Melatonin 1mg/ml Oral Solution was approved by the MHRA in the United Kingdom.
Insufficient Sleep and Insomnia Displays a Relation to Neurocognitive Difficulties in Early Adolescents
In a propensity score matched, longitudinal, observational cohort study, findings showed that there was an association between insomnia and neurocognitive function in children.
A Recap on National Muscular Dystrophy Awareness Month From the Muscular Dystrophy Association
Sharon Hesterlee, PhD, chief research officer, Muscular Dystrophy Association, discussed the events that happened in September for National Muscular Dystrophy Awareness Month.
The Application of Neurostimulation Devices in Detecting Seizures in Generalized Epilepsy
Mark Richardson, MD, PhD, spoke about the successes of thalamic neuromodulation for patients with generalized epilepsy in his presentation at the 2022 Congress of Neurological Surgeons.
Similar Retinal Measurements Observed in Potential NMOSD and Definite NMOSD
A cross-sectional study showed that retinal measurements in patients with “potential” neuromyelitis optica spectrum disorder were similar to those with definite neuromyelitis optica spectrum disorder.
Patients With Alzheimer Disease Negatively Impacted by the COVID-19 Pandemic
Tabby Khan, MD, MPH, spoke on the impact that the COVID-19 has had on patients with Alzheimer disease and how telehealth has helped with providing care for those patients during a pandemic.
Anti-CD20 Therapies in Late-onset Neutropenia Result in an Uncommon Adverse Event
A report on two patients with late-onset neutropenia resulted in an uncommon adverse event following anti-CD20 therapies.
Hospital Night Shift Workers Experience Poorer Sleep Quality and Circadian Rhythms
A study conducted via telemonitoring showed that hospital workers who performed night shifts had significant negative impacts on their sleep quality and circadian rhythms.
Presence of Insomnia Symptoms Associated With Alcohol-Related Harm
A survey based on young adult college students indicated that symptoms of insomnia might buffer the association with the acute physiological effects of alcohol, in part because it may heighten the sensitivity to alcohol.
COVID-19 Pandemic Related to Significant Increase in Insomnia Symptoms
Data from a systemic review suggests that the COVID-19 pandemic is associated with increased rates of subthreshold insomnia symptoms, but not with moderate or severe insomnia, among the global population.
Longer Periods Between Natalizumab Dosing Might Result in Increased T2 Lesion Count
New data from the NOVA trial showed differences in the number of T2 lesions in patients with relapsing-remitting multiple sclerosis at 72 weeks of treatment with natalizumab (Tysabri; Biogen), though seemingly driven by data from only 2 participants with extreme new or newly enlarging T2 hyperintense lesion numbers.
Rituximab Treatment Associated with Reduced Relapse Rate in AQP4-IgG Positive NMOSD and MOGAD
A study using patient data from John Hopkins showed that rituximab treatment was associated with reduced annualized relapse rates in AQP4-IgG seropositive NMOSD and MOGAD.
Day-of-injury Plasma GFAP and UCH-L1 Predict Functional Recovery After Traumatic Brain Injury
The TRACK-TBI cohort study revealed that patients with traumatic brain injury and a GCS score of 3 to 12 had a significant increase in the accuracy of prognostic accuracy of IMPACT models.
Combination of MSBASE Prediction Model and Multiple Sclerosis Severity Score Improves Accuracy of Individualized Prediction in MS
Data from a MSbase registry on patients with multiple sclerosis show in its findings that the incorporation of the Multiple Sclerosis Severity Score improved the prediction accuracy of relapses in MS.
Combination of Biomarkers Associated with Stronger Predictions of Progression in Parkinson Disease
Findings from a study on Parkinson disease revealed that combining blood biomarkers in addition with clinical measures with prognostics modelling are associated with a more vital prediction in disease progression.
High Flow Oxygen As Acute Therapy is Most Optimal for Headache Relief
Recent findings from a network meta-analysis suggest that high flow oxygen is more efficacious when compared with low flow oxygen for headache relief.
Cluster Headache Prevention Clinical Trials Need to Focus on Efficacy, Natural History of Disease
A narrative review revealed that cluster headache trials have been limited thus far, and that future trials should include novel outcome measures and adjusted end point timing.
Crenezumab Does Not Reduce Clinical Decline in Adults With Early Alzheimer Disease
In 2 phase 3 randomized placebo-controlled trials, findings showed that although crenezumab was well tolerated, it did not reduce clinical decline in participants with early Alzheimer disease.
Majority of Canadian Physicians Treat Primary Headache Disorders With Nonsteroidal Anti-inflammatory Drugs, Dopamine Receptor Antagonists
A national survey showed in its findings that NSAIDs alone and dopamine receptor antagonists are used commonly for treating primary headache disorders in Canadian emergency departments.
Ketogenic Diet Results in Reduced Weight, Fatigue, and Depression in Relapsing Multiple Sclerosis
In a recent phase 2 study, 6-months of ketogenic diet for people with relapsing multiple sclerosis resulted in a significant reduction in weight, fatigue, and depression, and improved quality of life.
Ublituximab Reduces Relapses Compared With Teriflunomide in Multiple Sclerosis
In a phase 3 trial, ULTIMATE I and II, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI than teriflunomide among participants with relapsing multiple sclerosis.
2 Clarke Drive Cranbury, NJ 08512